Browse articles from EyeWorld.org related to MIGS. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Enrollment complete in MIGS pivotal trial ➤ Acquisition of dry eye drop ➤ Two-year results post-cilio-scleral glaucoma procedure ➤ Positive topline results from Phase 2 study of retinitis pigmentosa treatment ➤ ASCRS news and events
➤ FDA approves ophthalmic spray for mydriasis ➤ FDA accepts NDA for travoprost intraocular implant ➤ FDA accepts supplemental BLA for treatment for macular edema ➤ FDA 510(k) clearance granted to green pattern laser photocoagulator ➤ NDA submitted for pain and inflammation nanoemulsion ➤ Positive clinical results from IOP-monitoring contact lens ➤ Study provides real-world data comparing MIGS using IRIS Registry ➤ FDA approves IOL positioning system ➤ ASCRS news and events
MIGS procedures have become a mainstay in the treatment of mild to moderate glaucoma, but what pressures can physicians realistically expect with these? Three surgeons spoke about this, as well as how MIGS can fit into the overall glaucoma management process and what to do if MIGS procedures don’t achieve the desired IOP.
Patients with glaucoma who need cataract surgery have many lens options available, and it’s important for physicians to present the potential benefits and risks so patients can make the best decision. Two experienced ophthalmologists discussed different lens options for glaucoma patients and important factors to consider.
Glaucoma Editor Manjool Shah, MD, talks about what readers can expect in the Glaucoma section of the issue, as well as the value of ASCRS and the Annual Meeting. He also welcomes the newest members of the Glaucoma Editorial Board.
The first-in-human trial and data for suprachoroidal outflow enhancement using a novel micro-interventional technology and first-in-class biostenting approach developed by Sean Ianchulev, MD, MPH, was published online in the British Journal of Ophthalmology in January.
“A fundamental and unanswered question concerning all MIGS devices is whether they have any measurable ability to help POAG patients retain their vision.” The authors of a study published in the American Journal of Ophthalmology sought to answer this question. The study is a post-hoc visual field analysis of the 5-year HORIZON trial.
➤ Clinical trial for new cataract surgery technology ➤ Topline results from Phase 2 trial investigating treatment for persistent corneal epithelial defect ➤ Update on sustained-release glaucoma implant and Glaukos cornea programs ➤ First patient enrolled in Phase 3 trial for presbyopia drop ➤ ASCRS news and events
Two physicians shared their reasons for and experiences with combining MIGS procedures.
When the term MIGS was first coined more than a decade ago, there were only a few options in the space. Since then, the MIGS space has grown significantly with many options addressing the same outflow pathway. As such, it might be time to start talking about MIGS in terms of procedural categories.